質子幫浦抑制劑市場－全球產業規模、佔有率、趨勢、機會和預測，按藥物類型、疾病分類、應用、地區和競爭格局分類，2020-2030年預測

2024年全球質子幫浦抑制劑市場規模為31.5億美元，預計到2030年將以4.87%的複合年成長率成長至41.9億美元。質子幫浦抑制劑是一類藥物，旨在透過不可逆地阻斷胃壁細胞的氫鉀ATP酶系統來減少胃酸分泌。全球質子幫浦抑制劑市場需求成長的主要促進因素是胃食道逆流、消化性潰瘍和其他酸相關胃腸道疾病在全球範圍內的日益普遍，以及老年人口的不斷成長，老年人更容易患上這些疾病。

主要市場促進因素

全球質子幫浦抑制劑（PPI）市場正經歷顯著成長，主要促進因素是胃食道逆流和消化性潰瘍的盛行率不斷上升，以及老年人口不斷成長導致胃腸道疾病易感性增加。胃食道逆流和消化性潰瘍等疾病的廣泛發生構成了對PPI的基本需求，因為PPI能夠有效控制酸相關症狀並促進癒合。

主要市場挑戰

質子幫浦抑制劑的長期安全性對其市場擴張構成了顯著挑戰。越來越多的臨床證據和監管機構對長期使用可能產生的不良反應的日益嚴格的審查，正日益影響醫療服務提供者的處方模式。

主要市場趨勢

先進的PPI製劑和遞送方式的創新是製藥業為提升治療效果、提高患者依從性並減輕潛在的長期副作用而不斷努力的推動力。這一趨勢包括開發新型藥物遞送系統和製劑，以期實現更快的起效或更長的療效。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球質子幫浦抑制劑市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依藥物類型（泮托拉唑、奧美拉唑、蘭索拉唑、埃索美拉唑、雷貝拉唑、右蘭索拉唑、其他）
  • 依疾病分類（潰瘍、胃食道逆流、其他）
  • 按應用（醫院、診所、其他）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美質子幫浦抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲質子幫浦抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區質子幫浦抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲質子幫浦抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲質子幫浦抑制劑市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球質子幫浦抑制劑市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Bayer AG
• AstraZeneca PLC
• Pfizer, Inc.
• Eli Lilly and Co Ltd
• Teva Pharmaceutical Industries Ltd
• Cadila Pharmaceuticals Ltd
• Johnson & Johnson
• Takeda Pharmaceutical Co Ltd
• Eisai Co Ltd

第16章：策略建議

第17章調查會社について,免責事項

The Global Proton Pump Inhibitors Market, valued at USD 3.15 Billion in 2024, is projected to experience a CAGR of 4.87% to reach USD 4.19 Billion by 2030. Proton Pump Inhibitors are a class of pharmaceutical compounds designed to reduce gastric acid secretion by irreversibly blocking the hydrogen/potassium adenosine triphosphatase enzyme system of gastric parietal cells. The global market for these agents is driven by the increasing worldwide prevalence of gastroesophageal reflux disease, peptic ulcer disease, and other acid-related gastrointestinal disorders, coupled with an expanding geriatric population more susceptible to such conditions.

Key Market Drivers

The global Proton Pump Inhibitors market experiences substantial growth, primarily propelled by the escalating prevalence of gastroesophageal reflux disease and peptic ulcers, alongside the expanding geriatric population's increased susceptibility to gastrointestinal disorders. The widespread occurrence of conditions such as GERD and peptic ulcers forms the foundational demand for PPIs, given their efficacy in managing acid-related symptoms and promoting healing. According to Frontiers, in Global, regional, and national burden of gastroesophageal reflux disease (1990-2021): age-period-cohort analysis and Bayesian projections, published in 2023, global GERD prevalence reached 825.6 million cases in 2021, underscoring the significant patient pool requiring effective acid suppression therapies.

Key Market Challenges

The long-term safety profile of Proton Pump Inhibitors presents a notable challenge to market expansion. Growing clinical evidence and heightened regulatory scrutiny regarding potential adverse effects linked to prolonged use are increasingly influencing prescribing patterns among healthcare providers. This necessitates more cautious consideration during patient consultations and can lead to reduced initiation of long-term PPI therapy. Consequently, patient adherence may also be impacted, as individuals become more aware of reported risks, potentially leading to earlier discontinuation of treatment. These dynamics directly impede the sustained growth of the Global Proton Pump Inhibitors Market by tempering the volume of new prescriptions and the duration of existing ones.

Key Market Trends

Innovation in advanced PPI formulations and delivery represents a crucial trend, driven by the pharmaceutical industry's continuous efforts to enhance therapeutic profiles, improve patient adherence, and mitigate potential long-term side effects. This focus includes developing novel drug delivery systems and formulations that offer faster onset of action or prolonged efficacy. For example, Takeda Pharmaceutical Company Limited, in its first-quarter fiscal year 2025 results announced in July 2025, reaffirmed its commitment to discovering and delivering life-transforming treatments in its core therapeutic areas, explicitly including gastrointestinal and inflammation, highlighting ongoing innovation in this critical space.

Key Market Players

• Bayer AG
• AstraZeneca PLC
• Pfizer, Inc.
• Eli Lilly and Co Ltd
• Teva Pharmaceutical Industries Ltd
• Cadila Pharmaceuticals Ltd
• Johnson & Johnson
• Takeda Pharmaceutical Co Ltd
• Eisai Co Ltd

Report Scope:

In this report, the Global Proton Pump Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Proton Pump Inhibitors Market, By Drug Type:

• Pantoprazole
• Omeprazole
• Lansoprazole Esomeprazole Rabeprazole
• Dexlansoprazole Others

Proton Pump Inhibitors Market, By Disease Allocation:

• Ulcers
• Gastroesophageal Reflux Disease
• Others

Proton Pump Inhibitors Market, By Application:

• Hospitals
• Clinic
• Others

Proton Pump Inhibitors Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Proton Pump Inhibitors Market.

Available Customizations:

Global Proton Pump Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Proton Pump Inhibitors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Pantoprazole, Omeprazole, Lansoprazole Esomeprazole Rabeprazole, Dexlansoprazole, Others)
  • 5.2.2. By Disease Allocation (Ulcers, Gastroesophageal Reflux Disease, Others)
  • 5.2.3. By Application (Hospitals, Clinic, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Proton Pump Inhibitors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Disease Allocation
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Proton Pump Inhibitors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Disease Allocation
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Proton Pump Inhibitors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Disease Allocation
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Proton Pump Inhibitors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Disease Allocation
      • 6.3.3.2.3. By Application

7. Europe Proton Pump Inhibitors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Disease Allocation
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Proton Pump Inhibitors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Disease Allocation
      • 7.3.1.2.3. By Application
  • 7.3.2. France Proton Pump Inhibitors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Disease Allocation
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom Proton Pump Inhibitors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Disease Allocation
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Proton Pump Inhibitors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Disease Allocation
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Proton Pump Inhibitors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Disease Allocation
      • 7.3.5.2.3. By Application

8. Asia Pacific Proton Pump Inhibitors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Disease Allocation
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Proton Pump Inhibitors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Disease Allocation
      • 8.3.1.2.3. By Application
  • 8.3.2. India Proton Pump Inhibitors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Disease Allocation
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Proton Pump Inhibitors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Disease Allocation
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Proton Pump Inhibitors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Disease Allocation
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Proton Pump Inhibitors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Disease Allocation
      • 8.3.5.2.3. By Application

9. Middle East & Africa Proton Pump Inhibitors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Disease Allocation
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Proton Pump Inhibitors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Disease Allocation
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE Proton Pump Inhibitors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Disease Allocation
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa Proton Pump Inhibitors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Disease Allocation
      • 9.3.3.2.3. By Application

10. South America Proton Pump Inhibitors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Disease Allocation
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Proton Pump Inhibitors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Disease Allocation
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia Proton Pump Inhibitors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Disease Allocation
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina Proton Pump Inhibitors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Disease Allocation
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Proton Pump Inhibitors Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bayer AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AstraZeneca PLC
• 15.3. Pfizer, Inc.
• 15.4. Eli Lilly and Co Ltd
• 15.5. Teva Pharmaceutical Industries Ltd
• 15.6. Cadila Pharmaceuticals Ltd
• 15.7. Johnson & Johnson
• 15.8. Takeda Pharmaceutical Co Ltd
• 15.9. Eisai Co Ltd

16. Strategic Recommendations

17. About Us & Disclaimer